NCT04021368View on ClinicalTrials.gov

RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

September 4, 2019

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Acute Myeloid LeukemiaHigh-risk Myelodysplastic Syndrome
Interventions
DRUG

RVU120(SEL120)

RVU120(SEL120) will be administered as a single oral dose every other day (q.o.d.) for a total of 7 doses i.e. on Days 1, 3, 5, 7, 9, 11 and 13, in a 3-week treatment cycle.

Trial Locations (10)

30342

Northside Hospital, Atlanta

33136

Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics, Miami

37203

Tennessee Oncology, Nashville

63110

Washington University School of Medicine, St Louis

77030

MD Anderson Cancer Center, Houston

80-214

Uniwersyteckie Centrum Kliniczne, Gdansk

87-100

MICS Centrum Medyczne Toruń, Torun

02-776

Instytut Hematologii i Transfuzjologii, Warsaw

53-413

Dolnośląskie Centrum Onkologii, Pulmonologii i Hematologii, Wroclaw

25-734

Świętokrzyskie Centrum Onkologii, Klinika Hematologii i Transplantacji Szpiku, Kielce

All Listed Sponsors
lead

Ryvu Therapeutics SA

INDUSTRY